Method for detoxification-infusion therapy of patients used psychotropic cannabis products

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to psychiatry and drug addiction, and may be used for detoxification-infusion therapy of the patients used psychotropic cannabis products. That is ensured by the infusion intravenous drop-by-drop sequential administration of drugs. A mixture containing 5% glucose 200 ml, 25% magnesium sulphate 10 ml and 4% potassium chloride 10 ml are administered. That is combined with the additional bolus administration of 5% vitamin B1 2 ml. That is followed by introducing a mixture containing 0.9% normal saline 200 ml and 20% piracetam 10 ml. That is added with the bolus administration of 5% vitamin B6 10 ml. Then, a mixture containing rheopolyglucin 200 ml, 5% ascorbic acid 5 ml and 1% nicotinic acid 1 ml is administered. Then, a mixture containing 0.9% normal saline 200 ml and 2.4% aminophylline 5 ml is administered. The procedure is performed twice a day for 10 days.

EFFECT: method provides the higher therapeutic effectiveness and reduced length of the therapy, as well as the presented method is reproducible easily.

1 ex

 

The present invention relates to medicine, namely to psychiatry, narcology, Transfusiology.

The proportion of patients with opioid dependence has decreased from 86% in 2005 to 80% in 2011, the percentage of patients cannabidiol addiction has not changed, patients with the syndrome of dependence on psychostimulants increased from 1% to 3%, of patients with polydrug use also increased from 5% to 9%. Identified changes in the primary uptake may indicate changes in the structure of consumption of drugs in the population [Statistical Bulletin "Main indicators of the performance of drug treatment services in 2011/ Under leadership. E.A. Cat - Moscow, 2012, http://www.nncn.ru/2_421.html].

Introduction in June 2011 prescription codeine drugs has become a significant barrier against the spread of this synthetic drug. As a result, at present again significantly increased the demand for heroin, cannabis and poppy straw [http://i-gazeta.com/narkostop/22288.html].

The structure of registered drug addicts: the vast majority were patients with opiate dependence (85,6%); the second rank took the place of patients with dependence on cannabis (6.8 percent); third, patients who use other drugs and combinations of different drugs (6,2%). The percentage of patients with the syndrome based on psychostimulation the small - 1,4%. Thus, most often for drug-treated patients of opium and cannabidiol drug addiction. In the last six years have seen an increase in the overall incidence of cannabinoid addiction: in 2005 Gatot rate was 15.5 patients per 100 thousand population, in 2011 - 16,1, i.e. for 6 years it increased by 3.9% [Statistical Bulletin "Main indicators of the performance of drug treatment services in 2011/ Under leadership. E.A. Cat - Moscow, 2012, http://www.nncn.ru/2_421.html].

Acute intoxication caused by the consumption of cannabinoids, is a transient condition that occurs after receiving cannabinoids, which causes disturbance or changes in physiological, psychological or behavioural functions and reactions. The duration of intoxication from 30 minutes to several hours. According to the International classification of diseases acute intoxication caused by the consumption of cannabinoids, belongs to the class of F12.0 [National manual on psychiatry./ Edited by T.B. Dmitrieva M: GEOTAR-Media, 2011 - s].

Hashish is the dried and laminated to a resinous substance that is extracted from the surface of the flowering tops of the Indian or American hemp ("cannabis indica", "cannabis americana"; hence the name "cannabible"). Most cannabinol in Indian hemp. Cannabible see also Fox is s and shoots of plants. In our country, other names for cannabis "marijuana", "plan", "the shit", "Pali". Active substance - Tetra-hydrocannabinol, so this form is also called Kanna-bialowas (or cannabidiol)drug addiction. The outcome of Hasidism - the so-called apatoabulicheskie syndrome resembling the final state, the defect in schizophrenia. This is an irreversible condition, defect. In addition, this drug is considered a "springboard"as if "opens the gate" to other drug addiction [http://www.sdelaysebiasam.ru/view_post.php?id=39].

Phase of intoxication with cannabis.

I. Manifested through 2-5 minutes. Characterized by feelings of fear, anxiety, suspicion. Duration 5-10 minutes

II. Relaxation, ease, complacency. Disorders of perception (individually impaired color vision, intensity of sound, space and body schema). Emotional distress in the form of complacency, sometimes fear. Typical easy solutions, carelessness in actions. The rate of accelerated thinking. Consciousness is narrowed, then stunned. Injection of the sclera.

III. Emotional confusion. Thinking with the characteristics of bessvatnet. Consciousness stunned. Emotional disorders are manifested in the form of violent imitation of affects (drunken laughs followed by a neighbor, but the joy of not experiencing). Blood pressure increased, tachycardia. In motor function lethargy.

IV. Pallor, lethargy, weak is here, the hypotension. Increased appetite. Clear consciousness. Soon comes the superficial sleep for 10-12 hours. When waking up the thirst, increased appetite. After drinking (even passive Smoking) cannabinoids and their metabolites detected in the urine for 3-4 weeks, depending on the intensity of use [http://narcologia.ru/narcomania-statyi-kanabioydi.html].

For "Galilei dependencies.

I Stage. Comes in 1.5-3 years after first use. In the intoxication disappears the first phase. The use of systematic, there is an active search for drug. Increasing tolerance. Manifested psychic dependence, manifested an obsessive attraction. The duration of this stage is 2-5 years.

II stage. Develops in 3-5 years from the start of the systematic use. You receive physical dependence. The fourth phase of acute intoxication disappears. The second and third phase of intoxication merge into one. In toxicity observed short psychosomatic relaxation, rapidly changing state of elation, physical activity, health, smestimosti, discipline. The rate of accelerated thinking. After intoxication (through 1-1,5 hours) comes the loss of tone and health. Tolerance to the drug reaches its maximum value. The drug becomes the means to achieve the necessary f the physical and mental comfort. Formed withdrawal syndrome.

Stage III. Formed after 9-10 years of systematic drug use. Tolerance decreases. The drug has only - toning effect. There has been a progressive reduction of the energy potential, physical and mental exhaustion, loss of social ties, dementia [http://narcologia.ru/narcomania-statyi-kanabioydi.html].

Diagnostic criteria of the syndrome of cannabinoids (ICD-10, F12.3x). Develops after the cessation of prolonged cannabis use in high doses. Symptoms include fatigue, apathy, hypobole, lower mood, anxiety, irritability, tremor, muscle pain, selectoption (chest tightness, shortness of breath, compression, and compression of the head, burning sensation and tingling under the skin), the withdrawal psychosis (delirium).

Phase withdrawal syndrome.

1. Manifested through 4-5 hours after ingestion. Pupils dilated, yawning, chills, lethargy, muscle weakness, anxiety, dysphoria, loss of sleep and appetite.

2. Manifested by the end of the first day after taking the drug. Increases in autonomic arousal. Muscles tense, fine tremor, hyperreflexia, increased blood pressure, increased heart rate, breathing, convulsive twitching of individual muscle.

3. Appears on the second day after taking the drug. Senesco eticheskie complaints. Heaviness, squeezing in the chest, shortness of breath, pain and compression of the heart, the compression head. On the skin and under it the sensation of burning, tingling, twitching, crawling. Tearfulness. In uncomplicated withdrawal develops asthenic depression, possible withdrawal psychosis within 3-5 days of abstinence. The duration of abstinence from 3-14 days to 1 month. Improving sleep and the appearance of symptoms indicate improvement. The withdrawal syndrome is formed after 8-12 months of systematic drug use [http://narcologia.ru/narcomania-statyi-kanabioydi.html].

There is a method of treatment of abstinence syndrome in heroin abuse, including treatment by a set of medications, including infusion means (gemodez, reopoliglyukin), drugs that regulate metabolic processes (kokarboksilaza, Riboxin, ascorbic acid, b vitamins), angioprotectors (piracetam, trental), and tranquilizers (phenazepam, Relanium) and analgesics (aspirin, baralgin, Pentalgin, ketamine, diclofenac-sodium), and then to overcome compulsive craving for heroin subsequent stage of treatment measures attributable usually for 3-4 days of therapy includes the use of dimefosfona intravenously 2 times a day from a rate of 60 mg/kg daily rates, and individual (course) treatment d is mephosfolan developed on the basis of the severity of heroin withdrawal syndrome, measured at a height of algenol symptoms (the period of "withdrawal" on a scale Kolb-Himmelsbach) [patent RU 2191019, 2002].

There is a method of treatment addiction, characterized in that the admission of the patient to the hospital to find out, among other things, the time of the last injection of the drug. If the patient does not have a pronounced withdrawal syndrome, i.e. after 4-8 hours after the last injection of the drug, the patient spend intravenous drip injection of ozonized physiological solution with ozone concentration of 300-500 µg/l On the second day subcutaneously injected ozone-oxygen mixture with ozone concentration in the gas phase 1200-1500 mg/l 1-2 ml of biologically active points of the cervical-collar zone, At 11 Meridian navel, UP pair on both sides and HS. Pain in the lumbar region and knee joints, calf muscles ozone-oxygen mixture is injected into the point of the lumbar region 25,UP and feet UP, UP pair on both sides. On admission the patient with a pronounced withdrawal syndrome after 12-16 hours after the last injection of the drug first injected ozone-oxygen mixture with ozone concentration in the gas phase 1200-1500 mg/l 1-2 ml of biologically active points of the cervical-collar zone, At 11 Meridian navel, UP pair on both sides and HS. Then enter in points the lumbar region 25,UP and feet UP, UP PA is but on both sides. After that carry out intravenous drip injection of ozonized physiological solution with ozone concentration of 300-500 mg/l Ozone therapy for 4-5 days. In parallel with the ozone therapy the patient is prescribed: analgesics (4-5 days), antidepressants (10 days), alpha blockers (5-7 days) and sedatives (10 days). Usually" withdrawal syndrome already removed on the 4th day. 5-6 day prescribed opiate receptor blockers - antonson 1 tablet 1 time a day for 10 days and the products of metabolic steps, for example, cytoflavin 10 ml to 200 ml of 5% glucose drip from 5 to 10 treatments [patent RU 2302227, 2007].

There is a method of relief of alcohol withdrawal syndrome, including medical therapy, colon hydrotherapy with a solution of sorbent, at the same time as drug therapy oral use aqueous suspension of the powder sorbent POLYSORB in the amount of 50-150 ml with a concentration of 1-1,5 g of powder per 1 kg of patient weight, then drip intravenous plazmozameschayuschie means of Plasma-lit 148 in an amount up to 1000 ml or Reamberin in a daily dose of 10 mg/kg, while colon hydrotherapy is performed using sorbent POLYSORB at a concentration of no more than 100-200 mg per 1 kg of body weight, followed by rectal insufflating gaseous Sonokeling the Noah mixture. thus an additional correction of psychopathological and neurovegetative disorders with the use of psychotropic drugs-tranquilizers, for example Phenazepam, nootropics such as Piracetam, Nootropyl, Picamilone, Fezana, "soft" neuroleptics, such as Chlorprothixene, Sonapaks and selective anxiolytics dibenzodiazepine number, for example Afobazole. Intravenous means of plasma-Plasma-lit 148 or Reamberine intravenous bolus injected Polyvitamin preparation Cernevit dissolved in 5 ml of water for injection or 5%glucose solution. Rectal insufflation of ozone-oxygen mixture is conducted by Janet's syringe with ozone concentration in the ozone-oxygen mixture of 10-60 mg/l and up to 150 ml. And the above procedure can be repeated for three days [patent RU 2327474, 2008].

There is a method of treatment of abstinence syndrome in humans with alcohol or opiates, namely, that the taurine in the number of 400-600 mg injected once daily in saline or 5%glucose solution. Taurine - 2-aminoetansulfonovaya acid, stimulates regenerative processes, pathologies accompanied by a sharp violation of metabolic processes. The invention provides a reduction in the duration and exp the debts of major withdrawal disorders and lack of side effects with alcohol and drug addiction [patent RU 2422139, 2011].

The prototype of the invention is a method of treatment of alcoholism and drug abuse with the use of medicine containing aqueous solutions of sodium chloride, ascorbic acid, vitamin B6, aminophylline, collicola, Dimedrol, Relanium, furosemide, nootropil magnesium sulfate. In the first stage, carried out psychosuggestive the impact of motivation on full recovery and refuse alcoholic and/or drug substances. At the second stage within 13-15 days conduct detoxication therapy, which includes deep cleansing of the intestinal aqueous solutions on the basis of extracts of medicinal plants; intravenous drug gemodez" on the basis of polyvinylpyrrolidone in the amount of 400-800 ml daily and a 10%aqueous solution of ascorbic acid in saline solution and/or water at the rate of 100-120 g of dry matter per day, oral administration of medicine by 100 ml 4 times a day and ascorbic acid in the amount of 15-20 grams per day. At the third stage for 2.5-3.5 months supportive herbal medicine oral administration of extracts from medicinal plants [patent RU 2181593, 2002]. The disadvantages of this method are the following circumstances: when it ignores the severity of anesthesia and medical history, drug use gemodez, which in the us is Aasee is not currently used in the treatment of patients, and ascorbic acid in large doses, other types of drugs are used in medicine, the method is time consuming and not efficient enough.

The task of the invention is to develop a method adequate desintoxicacion-infusion treatment of patients in the use of psychotropic products from hemp, providing increased efficiency and shorter duration of therapy.

The technical result - the reduction of the duration of treatment of patients in the use of psychotropic products from hemp.

The proposed method desintoxicacion-infusion treatment of patients in the use of psychotropic products from hemp is as follows. Consistently infusion intravenously injected integrated solutions: first, introduce a mixture containing solutions: glucose 5% - 200 ml magnesium sulfate 25% - 10 ml, potassium chloride 4% - 10 ml, advanced inkjet impose 5% solution of vitamin B12 ml and then introducing the mixture containing solutions: isotonic sodium chloride 0,9% - 200 ml, 20% piracetam - 10 ml, advanced inkjet impose 5% solution of vitamin B610 ml. Then injected mixture containing solutions: reopoligliukina - 200 ml ascorbic acid 5% - 5 ml nicotinic acid 1% - 1 ml Then injected mixture containing solutions: isotonic sodium chloride 0,9% - 200 ml of 2.4% solution of aminophylline 5 ml. The procedure is performed every day twice a day for 10 days, including the use of other methods of treatment: pharmacotherapy, psychotherapy, and autogenic training.

Pharmacological properties of glucose solution 5%. Plazmozameschayuschie, hydrating, metabolic, detoxification. The substrate provides energy metabolism. Supports volume of circulating plasma. Isotonic solution fills the volume of fluid lost, increased osmotic activity of hypertonic solutions increases the release of tissue fluid to the bloodstream and keeps her in it, increases diuresis and excretion of toxic substances. Molecules of dextrose utilized in the process of energy supply. Through participation in various processes of metabolism, glucose has a multifaceted effect on the body: increases the redox processes in the body, improves the antitoxic function of the liver. Infusion of glucose solution partially compensates for the water deficit. Glucose, in doing fabric fosfauriliruetsa into glucose-6-phosphate, which is actively involved in many stages of metabolism. Isotonic 5% glucose solution provides detoxification, metabolic action, is a valuable source of easily digestible nutrients in the society. When glucose metabolism in tissues allocated a significant amount of energy necessary for vital activity of the organism (http://onlinefarma.ru/infuzionnaya-terapiya/glyukozy-5-10-rastvor.html).

The pharmacological action of magnesium sulfate 25% solution. When parenteral sedative, diuretic, artedidraconidae, anticonvulsant, antiarrhythmic, hypotensive, antispasmodic, in large doses - curariform (a dampening effect on neuromuscular transmission), tokoliticheskoe, sedative and narcotic effects, inhibits the respiratory center. Regulates metabolism, mezhneyronalnoy transmission and muscular excitability, prevents the intake of Ca2+through the presynaptic membrane, reduces the amount of acetylcholine in the peripheral nervous system and Central nervous system. Relaxes smooth muscles, lowers blood pressure (mostly high), increases diuresis. Anticonvulsant action of Mg2+reduces the release of acetylcholine from the neuromuscular synapses, creating neuromuscular transmission, has a direct depressant effect on the Central nervous system. Antiarrhythmic action of Mg2+reduces the excitability of cardiomyocytes, restore ionic balance, stabilizes the cell membrane, violates the current Na+m is Glenny input current Ca 2+and unilateral current To+. Cardioprotective effect is due to the expansion of the coronary arteries, decreased SVR and platelet aggregation. Tokoliticheskoe action - Mg2+inhibits contractility of the myometrium (decrease absorption, binding and distribution of Ca2+in cells of smooth muscles), increases the blood flow in the uterus as a result of expansion of its vessels. Is an antidote for poisoning by salts of heavy metals. System effects develop almost immediately after intravenous and 1 h after intramuscular injection

(http://ru.wikipedia.org/wiki/%D1%F3%EB%FC%F4%EO%F2_%EC%E0%E3%ED%E8%FF_(%EB%E5%EA%E0%F0%F1%F2%E2%E5%ED%ED%EE%E5_%F1%F0%E5%E4%F1%F2%E2%EE)).

Potassium chloride - potassium salt of hydrochloric acid. Potassium is the main intracellular ion, which plays an important role in regulating body functions. The readings. Heart rhythm disorder, intoxication after administration of cardiac glycosides and diuretics, the lack of potassium in the body. Pharmacological action of potassium chloride. Normalizing the acid-base status, complementary deficit of potassium. Activates many cytoplasmic enzymes, regulates intracellular osmotic pressure, protein synthesis, amino acid transport, conduction of nerve impulses, contraction of skeletal muscles. Potassium ions cause ischemia of the heart rate, reduce socratically the activity, reduce conduction, automaticity and excitability of the myocardium. In small doses it expands coronary vessels, large - narrow. Potassium increases acetylcholine and the excitation of the sympathetic Central nervous system. Has a mild diuretic effect. The increase in potassium reduces the risk of toxic effects of cardiac glycosides on the heart. Potassium chloride after ingestion and easily in almost any number of passively absorbed. In the ileum and colon guts potassium is secreted into the lumen of the gut on the principle of risk sharing with sodium ions, and is excreted in the faeces (10%). The potassium in the body lasts about 8 hours from the time of admission: half-life phase removals - 1.31 hour (http://ru.wikipedia.org/wiki/%D5%EB%EE%F0%E8%E4_%EA%E0%EB%E8%FF).

Thiamine (vitamin B1) is a water - soluble vitamin, tiaminpirofosfat - active form of thiamine is a coenzyme piruvatcarboksilazy and α-ketoglutarates complexes, as well as transketolase. The first two enzymes involved in the metabolism of carbohydrates, transketolase operates in pentose-phosphate pathway, participating in the transfer glycoaldehyde radical between keto and aldosari. Tiaminpirofosfat is synthesized by the enzyme tiaminpirofosfata, mainly in the liver and in the brain tissue. The reaction requires the presence the Oia free thiamine, ions of Mg2+and ATP. Thiamine deficiency is a causal factor in the development of a number of serious disorders, the leading place being occupied by lesions of the nervous system. The complex effects of thiamine deficiency is known under the name of the disease beriberi. As a rule, the development of thiamine deficiency is associated with eating disorders. This may be caused by insufficient intake of thiamine from food, and can result from excessive consumption of products containing significant amounts antiliminal factors. When beriberi are weakness, weight loss, muscle atrophy, peripheral neuropathy, mental disorders, disorders of the digestive and cardiovascular systems, the development of paresis and paralysis. One of the forms of beriberi, occurring mainly in developed countries, is a syndrome of the Gaia-Wernicke (otherwise syndrome Wernicke-Korsakov), when developing alcoholism. When the metabolism of thiamine in the first place there is a disorder of oxidative decarboxylation of α-ketoacids and partially blocks the metabolism of carbohydrates. In patients with beriberi, the accumulation of oxidized products of metabolism of pyruvate, which have a toxic effect on the Central nervous system and contributes to the development of metabolic acidosis. Due to the development of reduced energy efficiency is Yunosti the ion gradient pumps, including cells of the nervous and muscle tissue. Impaired fatty acid synthesis and transformation of carbohydrates into fats. Increased protein catabolism leads to the development of muscle atrophy in children - delay physical development. Due to the difficulty in formation of pyruvic acid acetyl COA suffers process acetylation of choline.

Pharmacological action isotonic sodium chloride 0.9 per cent. A solution of sodium chloride 0,9% isotonic plasma human blood, it is often called "physiological". This title is conditional, as the solution does not contain other substances (salts of potassium, calcium and other)necessary to maintain physiological conditions of the tissues of the body. The solution is quickly removed from the vascular system and only temporarily increases the amount of fluid circulating in the blood vessels, so blood loss and shock, it is not efficient enough. In these cases it is necessary to perform a blood transfusion, plasma or fluid liquids. Relatively often used isotonic sodium chloride solution as a detoxification agent and dehydrating the body. Widely used for dissolution of various drugs, including the infusion. Enter isotonic sodium chloride solution intravenously, subcutaneously and enemas. Enter wew is Ivanna drip method for large losses of fluid and intoxication, in large quantities (up to 3 liters per day). You should not pour isotonic solution of sodium chloride with hypernatremia, circulatory disorders, threatening swelling of the brain and lungs, in the treatment with high doses of corticosteroids. Large volumes of solution should be used with caution in patients with impaired renal excretory function (http://ru.wikipedia.org/wiki/%D0%A4%D0%B8%D0%B7%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9_%D1%80%D0%B0%D1%81%D1%82%D0%B2%D0%BE%D1%80).

Piracetam (eng. Piracetam) is a nootropic drug. Piracetam is well absorbed by ingestion. With the introduction of the organism into the various organs and tissues, including brain tissue. There is metabolized. Excreted by the kidneys. The drug has a positive effect on metabolism and blood circulation of the brain, stimulates the oxidation-reduction processes, increases glucose utilization, improves regional blood flow in ischemic areas of the brain, and increases the body's energy potential. Improving energy processes under the influence of piracetam increases the resistance of brain tissue hypoxia and toxic effects. There is evidence of increased under the influence of piracetam nuclear RNA synthesis in the brain. Used to improve metabolic processes in the cerebral cortex at different the Central nervous system deseases, especially associated with vascular disorders and disorders of metabolic processes in the brain. Medicinal properties of piracetam is determined by its ability to enhance integrative brain activity and intellectual activity, to contribute to the consolidation of memory, improve the learning processes, to restore and stabilize brain function, including the elderly and senile age. In neurological practice prescribed for atherosclerosis, brain, vascular parkinsonism and other diseases with symptoms of chronic cerebral vascular insufficiency, manifested in disorders of memory, attention, speech, dizziness, and others, as well as changes of cerebral circulation, with comatose and subcomittee States after brain injury and poisoning, as well as during rehabilitation therapy after such conditions. Also used piracetam in diseases of the nervous system, accompanied by a decrease of intellectual-mnestic functions and disorders of the emotional-volitional sphere.

In psychiatric practice piracetam use in patients with neurotic and astrodynamicist depression of various origins with the prevalence of clinical signs of adynamia, asthenic, seneste-hypochondriac the violations, effects of ideational storojinet, as well as in vyaloapaticheskih defective conditions in patients with schizophrenia, organic mental syndromes of different etiology, senile and atrophic processes in the treatment of various mental illnesses. Piracetam can also be used as an aid in the treatment of patients with depression resistant to antidepressants, as well as poor tolerance of neuroleptics and other psychotropic drugs to eliminate or prevent caused by somatovegetative, neurological and psychiatric complications. Piracetam is also used for relief of withdrawal, pre - and delirious States in alcoholism and drug addiction, as well as in cases of acute alcohol poisoning, morphine, barbiturates, and other pyracetam in the complex of means to relieve the acute effects of alcohol abstinence reduces the severity of cerebral vascular disorders, reduces headaches, dizziness, feelings of apathy, drowsiness. In chronic alcoholism piracetam is prescribed to reduce the symptoms of asthenia, intellectual disability and other mental activities (http://ru.wikipedia.org/wiki/%CF%E8%F0%E0%F6%E5%F2%E0%EC).

Pharmacological action of vitamin b6(pyridoxinum). He needed to normalizecolorname the Central nervous system. In the phosphorylated form of vitamin B6 is part of the enzymes carrying out the process of decarboxylation and transamination of amino acids. He is actively involved in the metabolism of tryptophan, methionine, cysteine, glutamic and other amino acids in the biosynthesis of the neurotransmitters dopamine, norepinephrine, epinephrine, serotonin, histamine and GABA, improves lipid metabolism in atherosclerosis, increases diuresis. Pyridoxine is used in Hypo-and avitaminosis 6, toxemia of pregnancy, atherosclerosis, anemia (including sideroblasts), various leukopenia, diseases of the nervous system (radiculitis, neuritis, neuralgia, Parkinson's disease, little's disease), depression involutional age, acute and chronic hepatitis, seboreepodobnyy and decaborane dermatitis, shingles, eczema, psoriasis, exudative diathesis. Also appointed with air and sea sickness, Meniere's disease. In addition, a solution of pyridoxine hydrochloride prevents or reduces toxic effects (especially polyneuritis) in the treatment of anti-TB drugs (http://www.bogmark.com.ua/vitamin_B6/).

Pharmacological action reopoligliukina. 10% solution of polymer of glucose - dextran with a relative molecular mass 30000-40000 with the addition of isotonic sodium chloride solution. Reopoliglyukin is a drug neskovic the regular dextran. It reduces aggregation of blood cells, contributes to the displacement of fluid from the tissues into the bloodstream. In this regard, the drug increases the suspension properties of the blood, reduces its viscosity, helps to restore blood flow in small capillaries, has a detoxifying effect, prevents and reduces aggregation of blood cells. Reopoliglyukin excreted from the body mainly kidneys, in the first day displayed about 70%. Apply for violations of capillary blood flow, for the prevention and treatment of traumatic, surgical and burn shock; disorders of the arterial and venous circulation; for the treatment and prevention of thrombosis and thrombophlebitis, of disease; heart operations conducted with the use of cardiopulmonary bypass (to be added to the perfusion fluid); vascular and plastic. surgery to improve local circulation; for detoxification burns, peritonitis, pancreatitis, etc. (http://slovari.yandex.ru/~%D0%BA%D0%BD%D0%B8%D0%B3%D0%B8/%D0%A0%D0%9B%D0%A1/%D0%A0%D0%B5%D0%BE%D0%BF%D0%BE%D0%BB%D0%B8%D0%B3%D0%BB%D1%8E%D0%BA%D0%B8%D0%BD/)

Pharmacological action of ascorbic acid solution 5%. She participates in the regulation of oxidation-reduction processes, carbohydrate metabolism, clotting of the blood, regeneration of the tissues; increases the body's resistance to the peccia, reduces vascular permeability, reduces the need for vitamins B1B2, A, E, folic acid, Pantothenic acid. Involved in the metabolism of phenylalanine, tyrosine, folic acid, norepinephrine, histamine, iron, the absorption of carbohydrates, the synthesis of lipids, proteins, carnitine, immune responses, hydroxylation of serotonin, increases absorption of non-heme iron. Has antiplatelet and antioxidant properties. Regulates the transport of H+in many biochemical reactions, improves the utilization of glucose in the tricarboxylic acid cycle, involved in the formation of tetrahydrofolate acid and regeneration of the tissues, the synthesis of steroid hormones, collagen, procollagen. Supports the colloidal state of the intercellular substance and normal capillary permeability (inhibits hyaluronidase). Activates proteolytic enzymes involved in the metabolism of aromatic amino acids, pigments and cholesterol, contributes to the accumulation of liver glycogen. Due to the activation of the respiratory enzymes in the liver increases its detoxification and protein function, increases the synthesis of prothrombin. Improves bile secretion, restores the exocrine function of the pancreas and endocrine - thyroid. Regulate immunological reactions (activates SinTe the antibodies, The C3 component of complement, interferon), promotes phagocytosis, increases the body's resistance to infections. Inhibits the release and accelerates the degradation of histamine inhibits the formation of Pg and other mediators of inflammation and allergic reactions. In low doses (150-250 mg/day orally) improves complexing function of deferoxamine in chronic intoxication with drugs of Fe, which leads to an increased excretion of the latter (/%C0%F1%EA%EE%F0%E1%E8%ED%EE%E2%E0%FF_%EA%E8%F1%EB%EE%F2%E0).

Pharmacological action of nicotinic acid solution 1%. Vitamin and lipid-lowering agent. In the body of nicotinic acid is converted to nicotinamide, which is associated with the coenzyme of codehydrogenase I and II (NAD and NADP)carrying the hydrogen is involved in the metabolism of fats, proteins, amino acids, purines, tissue respiration, glycogenolysis, synthetic processes. Fills a deficit of vitamin e (vitamin B3), is a specific protivopellagricescoe means (deficiency of vitamin PP). Normalizes the concentration of lipoproteins in the blood. Has a vasodilating effect on the level of small vessels (including brain), stimulates microcirculation, has a weak anticoagulant effect (increases fibrinolytic activity of blood). Indications for use are vitamin PP. Ischemic disorders mosgeogidrogeodeziya, obliterating vascular diseases of the extremities (obliterating endarteritis, Raynaud's disease), spasm of the limbs, bile and urinary tract (http://ru.wikipedia.org/wiki/E375).

Aminophylline (Euphyllinum). Effect of aminophylline is caused primarily by the presence of theophylline. Ethylenediamine increases skin activity and promotes the dissolution of the drug. Molecular mechanism of action of aminophylline basically similar to the mechanism of action of theophylline. Like theophylline, aminophylline relaxes bronchial muscles, lowers the resistance of the blood vessels, dilates coronary vessels lowers the system pressure of the pulmonary artery increases renal blood flow, has a diuretic effect, mainly associated with the decrease in tubular reabsorption; causes an increase in the excretion of urine water and electrolytes, especially sodium and chlorine ions. The drug is strongly inhibits platelet aggregation. The drug improves renal blood flow and can be used with appropriate indications. (http://dic.academic.ru/dic.nsf/meditem/2766).

The volume of infusion therapy when conducting detoxification on average was equal to the physiological needs of the organism in a liquid that is 2400 ml for an adult Intensive therapy of burn disease / Chiguanco E. [and others]; - M: Representors, 2005. - 144 S.).

Velicina circulating blood volume due to infusion solutions in combination with drugs provides improved renal blood flow, the formation of primary urine, which subsequently leads to increased excretion of metabolites in the use of psychotropic products from hemp.

In the available sources of medical research and patent information by the authors was not found identical way way desintoxicacion-infusion treatment of patients in the use of psychotropic products from hemp, including sequential infusion intravenous solutions of electrolytes, glucose, colloids, magnesium sulfate, potassium chloride, pyracetam, pentoxifylline, ascorbic and nicotinic acid. Thus, the claimed invention meets the criterion of "Novelty".

The authors proved that the proposed method. infusion therapy in trophic wounds, including sequential infusion intravenous solutions of electrolytes, glucose, colloids, novocaine, magnesium sulfate, pentoxifylline, ascorbic and nicotinic acid, provides an improvement of microcirculation and course of metabolic processes, stimulation of healing of trophic wounds. Thus, the claimed invention meets the criterion of "Inventive step".

This method was used in the treatment of 30 patients with trophic wounds in burn Department MBUS GKB №18, Ufa. In all cases reaches the specified technical result.

The invention is illustrated in the following clinical example.

Patient S 29 years, the case history No. 220987, sought treatment in the Republican narcological dispensary in the state of withdrawal symptoms from prolonged Smoking of taking psychotropic products from hemp. From the anamnesis it is known that for more than 10 years had used psychotropic products from hemp, often Smoking technique, but in other ways. Marked the third phase of withdrawal symptoms on the second day after the last dose. Selectoptions complaints. Heaviness, squeezing in the chest, shortness of breath, pain and compression of the heart, the compression head. On the skin and under it the sensation of burning, tingling, twitching, crawling. Tearfulness. Began to develop asthenic depression.

For "Galilei" based on the third stage. Formed after 9-10 years of systematic drug use. Tolerance is lowered. The drug has only tonic effect. There has been a progressive reduction of the energy potential, physical and mental exhaustion, loss of social ties, dementia.

Immediately after receiving started desintoxicacion-infusion treatment in the use of psychotropic products from hemp, proposed method, infusion intravenously injected is integral solutions: first, introducing the mixture, containing solutions: glucose 5% - 200 ml magnesium sulfate 25% - 10 ml, potassium chloride 4% - 10 ml, advanced inkjet impose 5% solution of vitamin B12 ml and then introducing the mixture containing solutions: isotonic sodium chloride 0,9% - 200 ml, 20% piracetam - 10 ml, advanced inkjet impose 5% solution of vitamin WB 10 ml. Then injected mixture containing solutions: reopoligliukina - 200 ml ascorbic acid 5% - 5 ml nicotinic acid 1% - 1 ml Then injected mixture containing solutions: isotonic sodium chloride 0,9% - 200 ml of 2.4% solution of aminophylline 5 ml Daily twice a day spent integrated cycle desintoxicacion-infusion treatment for 10 days on the background of other psychopharmakotherapie methods of psychotherapeutic methods (group psychotherapy) and autogenic training aimed at raising willpower.

As a result of treatment method proposed has escaped development withdrawal psychosis. Abstinence lasted for 3 days. In subsequent improved health, normalized sleep, was marked improvement. On the test urinalysis ten days traces of the use of psychotropic products from hemp is not found.

On day 14, the patient was discharged, according to medical-economic standards in a satisfactory condition.

Before agemy way to easily reproduce in the hospital and when it is achieved the specified technical result. Thus, the claimed invention meets the criterion of "Industrial applicability".

The way desintoxicacion-infusion treatment of patients in the use of psychotropic products from hemp, including the introduction of sodium chloride, ascorbic acid, vitamin B6, aminophylline and magnesium sulfate, characterized in that the introduction is carried out intravenous infusion drip consistently, initially introduced mixture containing 5% glucose solution in an amount of 200 ml, 25% solution of magnesium sulfate in an amount of 10 ml and 4% solution of potassium chloride in an amount of 10 ml, advanced inkjet impose 5% solution of vitamin B1 in the amount of 2 ml, and then introducing the mixture containing isotonic sodium chloride 0,9% in 200 ml of 20% solution of piracetam in the amount of 10 ml, advanced inkjet impose 5% solution of vitamin B6 in the amount of 10 ml; then introducing the mixture containing reopolyglykin in the amount of 200 ml, 5% solution of ascorbic acid in 5 ml of 1% solution of nicotinic acid (1 ml; thereafter introducing the mixture containing isotonic sodium chloride 0.9% in 200 ml of 2.4% solution of aminophylline in an amount of 5 ml, and the procedure is carried out every day twice a day for 10 days.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to using a purine derivatives for preparing drug preparations for treating chronic lymphocytic leukaemia and polycystic kidneys.

EFFECT: invention provides preparing the compounds possessing higher activity on lymphocytic leukaemia and polycystic kidneys.

8 cl, 3 dwg, 1 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to new heteroaryl compounds of general formula (I) and their pharmaceutically acceptable salts possessing the properties of protein kinase inhibitor, such as mTOR, IKK-2, Tyk2, Syk-kinase. In formula (I) R1 represents substituted or unsubstituted C1-8alkyl, substituted or unsubstituted aryl, specified in phenyl, substituted or unsubstituted 5-6-member heteroaryl with 1-3 nitrogen atoms in a cycle specified in pyridine, pyrazole, indole, indazole, triazole, benzimidazole, 2-(1H-imidazo-[4,5-b]pyridine, substituted or unsubstituted 5-7- member cycloalkyl or substituted or unsubstituted heterocycloalkyl specified in pyrrolidinyl; -X-A-B-Y- taken together form -N(R2)CH2C(O)NH-, -N(R2)C(O)CH2NH-, -N(R2)C(O)NH-, -N(R2)C=N- or -C(R2)=CHNH-; L represents a direct bond, NH or O; R2 represents substituted or unsubstituted C1-8alkyl, substituted or unsubstituted aryl specified in phenyl, tetrahydronaphthalene, unsubstituted 5-7- member mono- or 8- member bicycloalkyl; and R3 and R4 independently represent H or C1-8alkyl. The substitutes in the substituted groups are specified in one or more halogen, C1-8alkyl, hydroxyl, amino, nitro, thiol, C1-4alkyl thioether, cyano, carboxyl, C1-4alkyl ester, halogen alkyl, C6cycloalkyl or heteroaryl specified in pyridyl, triazole, O-lower alkyl, aryl specified in phenyl, phenyl-lower alkyl, CO2CH3, CONH2, OCHF2, CF3 or OCF3 groups wherein CONH2 group may be substituted by cyclohexyl.

EFFECT: compounds can find application for treating or preventing cancer, inflammatory pathological conditions, metabolic pathological conditions.

24 cl, 8 dwg, 2 tbl, 169 ex

FIELD: chemistry.

SUBSTANCE: disclosed agent is a xanthine derivative of formula 1

, where R1 denotes CH3, R2 denotes CH3; R3 denotes halogens: F,Cl, Br, I; R4 denotes hydrogen; R1 denotes CH3, R2 denotes CH3; R3 denotes hydrogen, halogens: F, Cl, Br, I; R4 denotes CH2COOH; R1 denotes hydrogen, R2 denotes CH3; R3 denotes halogens: F, Cl, Br, I; R4 denotes CH3. The preferred compounds of the said agent are 8-chlorotheophylline, 8-bromotheophylline and theophylline-7-acetate. The invention also relates to a method of slowing down proliferation of tumour cells and a method of inducing differentiation in mouse melanoma B16-F10 cells. Each of the methods involves addition of an effective amount of the said agent in an effective amount, preferably in amount of 1 mM.

EFFECT: improved properties of the derivatives.

8 cl, 4 tbl, 12 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds, which inhibit HIV replication, of formula (I) , its pharmaceutically acceptable additive salt; or stereochemically isomer form, where -a1=a2-a3=a4-represents bivalent radical of formula -CH=CH-CH=CH- (a-1); -b1=b2-b3=b4 -represents bivalent radical of formula -CH=CH-CH=CH- (b-1); n represents 0; m represents 1, 2; -A-B- represents bivalent radical of formula -CR5=N- (c-1); -N=N- (c-2); -CH2-CH2- (c-3); -CS-NH- (c-4); -CH=CH- (c-6); R1 represents hydrogen; R2a represents cyano; R3 represents cyano-substituted C1-6alkyl; cyano-substituted C2-6lkenyl; each of R4 independently represents halogen or C1-6alkyl; Q represents hydrogen or C1-6alkyl; R5 represents hydrogen, C1-6alkyl, aryl, pyridyl, thienyl, furanyl, amino, mono- or di(C1-4alkyl)amino, where aryl represents phenyl. Invention also relates to pharmaceutical composition, application and method of obtaining compounds.

EFFECT: obtaining novel compounds, which inhibit HIV replication.

5 cl, 25 dwg, 7 tbl, 16 ex

Novel compounds // 2395511

FIELD: chemistry.

SUBSTANCE: present invention relates to novel xanthine derivatives of general formula (I) and their pharmaceutically acceptable salts which have HM74A receptor activity, which can be used in therapy for treating diabetic dyslipidemia, combined dyslipidemia, heart failure, hypercholesteremia, atherosclerosis, arteriosclerosis, hypertriglyceridemia, type II sugar diabetes, type I diabetes, insulin resistance, hyperlipidemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, stenocardia, chronic kidney disease, peripherical vascular disease or stroke. In compounds of formula (I) , R1 is hydrogen or methyl; R2 is unsubstituted H-C4-6 alkyl; and R3 is chlorine.

EFFECT: obtaining novel compounds and a pharmaceutical composition based on the said novel xanthine derivatives.

15 cl, 54 ex

FIELD: medicine, pharmacology, organic chemistry, pharmacy.

SUBSTANCE: invention relates to novel compounds of the formula (I) promoting the defecation. Also, invention relates to a pharmaceutical composition containing these compounds and a method for promoting defecation and a method for treatment or relief of constipation. Proposed compounds possess the enhanced effectiveness.

EFFECT: valuable medicinal properties of pharmaceutical composition.

14 cl, 11 tbl, 55 ex

FIELD: organic chemistry, neurology, medicine.

SUBSTANCE: invention relates to a new medicinal agent used in treatment of feeble-mindedness comprising a derivative of 2-aryl-8-oxodihydropurine, namely, a derivative of 2-aryl-8-oxodihydropurine that comprises acetamide group at position 7 or 9 of purine ring. Invention proposes compounds of formulae (Ia) and (Ib) wherein radicals X1, Y1, R12, R13, R22, R23, R32, R42 and R43 have the corresponding values, or their pharmaceutically acceptable acid-additive salt. Also, invention proposes using compounds of the formulae (Ia) and (Ib) or their pharmaceutically acceptable acid-additive salt for preparing a medicinal agent used in treatment or prophylaxis of feeble-mindedness wherein feeble-mindedness represents deterioration of the teaching process, dysmnesia, dysmnesia-based disorientation, mental dysfunction, Alzheimer's disease, cerebrovascular feeble-mindedness and/or senile feeble-mindedness, and in treatment or prophylaxis of higher cerebral dysfunction. Invention provides the development of a medicinal preparation for prophylaxis or treatment of feeble-mindedness symptoms associated with diseases that can induce feeble-mindedness and higher cerebral dysfunction.

EFFECT: valuable medicinal properties of agents.

12 cl, 3 tbl, 5 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention describes a method for preparing 1,3-oxathiolan nucleosides or a method for preparing derivatives of 1,3-oxathiolanyl-5-one that involve effective methods for formation of 1,3-oxathiolan ring followed by condensation of 1,3-oxathiolan with pyrimidine or purine base. Using indicated methods these compounds can be synthesized as separate enantiomers with high selectivity.

EFFECT: improved preparing methods.

27 cl, 3 dwg, 16 ex

The invention relates to the field of medicine, biology, physiology, politicologie and is intended to reduce the content and excretion of uric acid from the body

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and describes a disulphiram implant for treating the alcohol or opiate addictive patients. The implant contains disulphiram 95.0-59.0 wt %, nitrogen polymer composition 4.8-40.5 wt % and stearic acid or magnesium stearate 0.2-0.5 wt %. The nitrogen polymer composition contains N-vinylpyrrolidone and 2-methyl-5-vinylpyridine copolymer or salts of branched oligomers hexamethylene diamine and guanidine, and polyvinylpyrrolidone.

EFFECT: implant may be used in addictology and provides a prolonged and uniform release of disulphiram with improving incisional wound healing.

5 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented methods of treating or preventing an addiction or recurrent addictive behaviour, including: alcohol, nicotine, marijuana, marijuana derivative, opioid receptor antagonist, benzodiazepine, barbiturate and psychostimulant by administering the peroxisome proliferator-activated receptor gamma (PPARγ) agonist thiazolidinedione, alone or in a combination with another therapeutic agent - an opioid receptor agonist, a mixed partial opioid receptor agonist/antagonist, an anti-depressant, an antiepileptic agent, an antiemetic agent, a corticotrophin releasing factor 1 (CRF-1) receptor antagonist, a selective serotonin 5-HT3 receptor antagonist, a 5-HT2A/2C antagonist or a cannabinoid 1 (CB1) receptor antagonist (versions), related pharmaceutical compositions with the above combinations (versions), a standard dosage form (versions) and kits (versions).

EFFECT: it is shown that the PPARγ agonist pioglitazone had no effect on amphetamine sensitisation, however it reduced opiate consumption and opiate addiction, also reduced nicotine self-administration in rats, and reduced alcohol consumption if synergistically combined with topiramate Pioglitazone reduced ethanol self-administration in rats.

33 cl, 23 dwg, 27 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmacology, and concerns the new application of 5-ethoxy-2-[2-(morpholino)ethylthio]-benzimidazole dihydrochloride (the anxiolytic Afobazole) as a medication for withdrawal syndrome management in opiate dependence. It is shown that Afobazole administered in a single or sub-chronic dose decreases the manifestations of 'spontaneous' or naloxone-caused morphine withdrawal syndrome, i.e. decreases physical morphine dependence.

EFFECT: anxiolytic Afobazole represents an effective medication for correcting the clinical manifestations of opiate withdrawal syndrome.

3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a drug preparation containing 97.0-59.5 wt % of naltrexone base, 0.5-3.0 wt % of corticosteroid specified in triamcinolone, betamethasone or dexamethasone, 2.0-37.0 wt % of a nitrogen-containing polymer composition and 0.2-0.5 wt % of stearic acid or magnesium stearate. The nitrogen-containing polymer composition contains N-vinylpyrrolidone and 2-methyl-5-vinylpyridine copolymer or a salt of branched oligomers hexamethylene diamine and guanidine, and polyvinylpyrrolidone. The drug preparation may be used in addictology for treating the alcohol- or opioid-dependent patients.

EFFECT: invention provides prolonged and uniform naltrexone release with a lower probability of the implant rejection caused by an inflammatory response.

2 cl, 3 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to pharmaceutical industry and deals with disulfiram-based medication, which additionally contains corticosteroid. Medicine contains 59.5-97.0 wt % of disulfiram base, 0.5-3.0 wt % of corticosteroid, 2.0-37.0 wt % of nitrogen-containing polymer composition and 0.2-0.5 wt % of stearic acid or magnesium stearate. Composition of nitrogen-containing polymers includes copolymer of N-vinylpyrrolidone and 2-methyl-5-vinylpyridine or salts of dissolved oligomers of hexamethylenediamine and guanidine and polyvinylpyrrolidone.

EFFECT: medication can be applied in addictology for treatment of alcohol or opiate-dependent patient.

2 cl, 4 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and represents a method for detoxification infusion therapy of drug-impaired patients involving the introduction of an infusion preparation and preparations enhancing the somatic state, differing by the fact that the therapy is prescribed once admitted to hospital and starts with measuring the extent of the infusion therapy by determining a degree of narcotisation manifestation, namely the presence of changed response syndrome, psychological dependence syndrome (obsession), physical dependence syndrome (compulsion) and withdrawal syndrome, body weight and daily physiological requirements that is followed by calculating the extent of the infusion therapy by formula: U=Kn×(Ks×MT)+PR; the infusion preparations are presented by electrolyte/glucose/colloid solutions in the ratio 3:3:1; it is added with psychopharmacotherapy; the therapeutic course makes 5-7 days in case of observing changed response, 10-14 days in case of psychological dependence, 15-21 days in case of physical dependence, 22-30 days in withdrawal syndrome with the extent of the infusion therapy calculated by formula is divided on 3 portions and administered in the patient at regular intervals within one day; if the patient is unassisted to compensate physiological requirements, the amount of parenteral solutions is reduced respectively.

EFFECT: invention provides adequate detoxification infusion therapy of patients in desomorphine consumption, higher effectiveness and reduced length of the therapy.

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted cyclohexylmethyl derivatives, having serotonin, noradrenaline or opioid receptor inhibiting activity, optionally in form of cis- or trans-diastereomers or mixture thereof in form of bases or salts with physiologically compatible acids. In formula (1): R2 denotes H or OH; R1 and R2 together denote or =N-OH, R3 denotes a phenyl residue which is unsubstituted or monosubstituted with a halogen atom or a heteroaryl residue selected from a five-member sulphur-containing heteroaryl such as a thienyl residue or an unsubstituted phenyl residue bonded through a C1-C4alkyl group, R4 and R5 independently denote an unsubstituted C1-C3alkyl or R4 and R5 together denote (CH2)3-6, R8 denotes a linear saturated C1-C4 alkyl group bonded with an aryl, which is unsubstituted or monosubstituted with halogen atoms, R9 denotes a saturated C1-C8alkyl; values of radicals R1, m, n, R6, R7, R10-R13 are given in the claim. The invention also relates to methods of producing compounds of formula (I), a medicinal agent containing said compounds, use of compounds of formula (I) to prepare a medicinal agent for anaesthetic treatment during sharp, neuropathic or chronic pain and for treating depression, urinary incontinence, diarrhoea and alcoholism.

EFFECT: high efficiency of using the compounds.

32 cl, 501 ex, 21 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition for pain management, as well as to application of said composition for making a drug for pain management. The declared composition contains a number of multilayer pills containing a water-soluble core, an antagonist layer containing HCI naltrexone and coating the core, an isolating polymer layer coating the antagonist layer, an agonist layer coating the isolating polymer layer, a delayed-release shell coating the agonist layer, an agent layer regulating osmotic pressure and containing sodium chloride immediately under the agonist layer. The isolating polymer layer contains acrylic-methacrylic ester polymers with quaternary ammonium groups, sodium lauryl sulphate in the amount of 1.6 wt % to 6.3 wt % and talc in the amount of 75 wt % to 125 wt % in relation to acrylic-methacrylic ester polymers with quaternary ammonium groups. The agonist layer contains morphine sulphate and hydroxypropyl cellulose, while sodium lauryl sulphate is found in the multilayer pills only in the isolating polymer layer.

EFFECT: invention provides preparing the pharmaceutical composition wherein the antagonist and agonist are isolated from each other, and the antagonist does not release from the composition due to osmotic pressure.

9 cl, 1 tbl, 23 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of general formula in which R1 represents C1-C10-alkyl with a straight or branched chain, optionally substituted by an aromatic ring, or -(CH2)nX(CH2)n- in which each n is equal to an integer from 0 to 2, X represents O, S, NH and where R2 represents H or C1-C6-alkyl with the straight or branched chain. Also, the invention refers to application of buprenophine derivative esters on a hydroxyl group of phenol for treating opiate dependences and/or moderate to strong pain, and to application as an agent releasing a therapeutic amount of buprenophine into a human body.

EFFECT: preparation of new buprenophine derivatives a hydroxyl group of phenol for treating opiate dependences and/or moderate to strong pain.

20 cl, 7 dwg, 1 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: described are dosed forms of guanfacine for per oral application, suitable for single intake per day, which has acceptable general size of pills.

EFFECT: dosed form by invention ensures satisfactory pharmacological profile for prolonged delivery of guanfacine during period of time up to 24 hours with regulated total weight of dosed form.

79 cl, 1 dwg, 2 tbl, 5 ex

Heamostatic match // 2501556

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a haemostatic agent used in small cuts, characterized by the fact that it is represented in the form of a match with its head having the following formulation, wt %: sodium chloride - 0.58 - 0.71; ε-aminocaproic acid - 2.14 - 3.25; purified water - 60.93 - 73.98; aluminium potassium sulphate - 19.65 - 32.84; lanolin - 1.77 - 2.92.

EFFECT: invention provides creating the agent which has the non-burning haemostatic agent when applied on the small cuts.

10 ex

Up!